Business Context and Reporting Period
This Form 8-K filing by aTyr Pharma, Inc. (Delaware) reports events occurring on April 10, 2019. The company is a biopharmaceutical firm focused on therapeutic programs, specifically mentioning the advancement of its ATYR1923 program.
Key Financial Metrics and Capital Structure
- Financing Transaction: Entered into a securities purchase agreement for a registered direct offering.
- Shares Issued: 9,242,143 shares of common stock.
- Purchase Price: $0.541 per share.
- Gross Proceeds: Approximately $5.0 million.
- Post-Offering Outstanding Shares: 45,742,332 shares.
- Use of Proceeds: Primarily to advance the ATYR1923 therapeutic program and for general corporate purposes.
- Closing Date: Expected on April 12, 2019.
The filing text does not provide specific values for revenue, profit, cash flow, margins, or existing debt levels.
Material Changes and Corporate Actions
- Capital Raise: The company secured approximately $5.0 million in new equity capital.
- ATM Suspension: The company notified Cowen and Company, LLC of the suspension and termination of its existing prospectus supplement for an "at-the-market" (ATM) offering. No further sales will occur under the existing Sales Agreement until a new prospectus supplement is filed.
Outlook, Risks, and Management Commentary
Management intends to utilize the new capital to advance the ATYR1923 therapeutic program. The filing notes that the Purchase Agreement contains customary representations, warranties, and indemnification obligations. The company is identified as an emerging growth company.
Investor Verification Checklist
- Verify the final closing of the $5.0 million offering on or around April 12, 2019.
- Confirm the updated share count of 45,742,332 shares post-offering.
- Monitor the filing of a new prospectus supplement if the company intends to resume ATM sales.
- Review the specific terms of the Securities Purchase Agreement (Exhibit 10.1) for any restrictive covenants.
- Assess the dilution impact of the 9.2 million new shares on existing shareholders.